Teva Pharma (TEVA) Tops Q4 EPS by 17c, FY18 Guidance Falls Short of Views
Teva Pharma (NYSE: TEVA) reported Q4 EPS of $0.93, $0.17 better than the analyst estimate of $0.76. Revenue for the quarter came in at $5.5 billion versus the consensus estimate of $5.31 billion.
GUIDANCE:
Teva Pharma sees FY2018 EPS of $2.25-$2.50, versus the consensus of $2.94. Teva Pharma sees FY2018 revenue of $18.3-18.8 billion, versus the consensus of $19.26 billion.
For earnings history and earnings-related data on Teva Pharma (TEVA) click here.